Autolus Therapeutics (NASDAQ: AUTL) reported Q4 EPS of ($0.52), versus ($1.42) reported last year.

"In 2019, we expect significant progress that will build on the momentum of last year," stated Dr. Christian Itin, chairman and chief executive officer of Autolus. "Our robust pipeline of clinical and pre-clinical programs is progressing well, and we expect to move two programs into registrational trials and provide updates on all of our active programs at conferences during the course of this year. The next scheduled data presentation will be for AUTO1 in adult acute lymphoblastic leukemia at the American Association for Cancer Research\'s Annual Meeting in April."

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.